The recent Thai phase III clinical trial (RV144) combining, in a prime-boost strategy, the recombinant poxvirus vector ALVAC and the protein gp120 and showing a 31.2% of protection against HIV infection [1], has raised considerable interest in the use of improved attenuated poxvirus recombinants as HIV vaccine candidates. This evidence concerns the gene ITIH4 and HIV infectious disease.